| abstract |
A method of targeting, treating or diagnosing malignant mammalian tumor cells comprising administering to a mammal an effective amount of a β1,6-branched oligosaccharide specific binding agent. As a therapeutic, the binding agent may be cytotoxic in nature, can cause an endogenous cytotoxic cascade, or can play a role in a cytotoxic cascade that is related to exogenous factors. The preferred binder is Bordetella pertussis, which is dedicated to β1,6-branched oligosaccharides and has good durability. Genetically modified microorganisms can also be used. The pharmaceutical composition can also serve as a binder. |